Physician profile
Hussein A Hussein
NPI 1154654648
$2,238.61
in general payments reported to CMS, 2019-2025
35 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $804 · 2023: $380 · 2024: $559 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.05 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $379.07 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $261.34 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $222.53 | 2021-2024 | |
| Glaxosmithkline, LLC. | $146.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $127.72 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $118.48 | 2022-2024 | Acthar |
| Amgen INC. | $97.61 | 2021-2024 | Krystexxa, Repatha |
| Ardelyx, INC. | $77.22 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $72.80 | 2023-2024 | Farxiga |
| Pharmacosmos Therapeutics INC. | $66.37 | 2023 | Monoferric |
| Lilly USA, LLC | $53.59 | 2021-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.89 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $47.37 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $45.04 | 2022-2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $37.57 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $32.35 | 2022-2023 | Afrezza |
| Ibsa Pharma INC. | $29.62 | 2022 | |
| Calliditas Therapeutics US INC. | $28.77 | 2022-2023 | Tarpeyo |
| Axonics, INC. | $27.02 | 2023 | Axonics |
| Aroa Biosurgery Incorporated | $26.16 | 2025 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Vifor Pharma, INC. | $23.75 | 2022 | |
| American Regent | $22.62 | 2023 | Injectafer |
| Daiichi Sankyo INC. | $22.58 | 2023 | Injectafer |
| Alvogen INC | $21.93 | 2023 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.75 | 2022 | |
| Dexcom, INC. | $19.87 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.16 | 2021 | |
| Recordati_rare_diseases_inc. | $17.76 | 2021 | |
| Abbvie INC. | $17.31 | 2024 | |
| Currax Pharmaceuticals LLC | $17.18 | 2024 | Contrave |
| Scpharmaceuticals INC. | $17.07 | 2025 | |
| Amag Pharmaceuticals, INC. | $15.73 | 2021 | |
| Travere Therapeutics, INC. | $9.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.